Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EPS (Basic) (2016 - 2025)

Bioadaptives' EPS (Basic) history spans 7 years, with the latest figure at -$0.07 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 37.67% to -$0.07 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.15, a 33.97% decrease, with the full-year FY2025 number at -$0.13, down 17.94% from a year prior.
  • EPS (Basic) hit -$0.07 in Q4 2025 for Bioadaptives, down from -$0.03 in the prior quarter.
  • Over the last five years, EPS (Basic) for BDPT hit a ceiling of -$0.0 in Q3 2024 and a floor of -$0.12 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$0.02 across 5 years, with a median of -$0.0 in 2021.
  • Biggest five-year swings in EPS (Basic): surged 98.37% in 2023 and later tumbled 105647.06% in 2025.
  • Tracing BDPT's EPS (Basic) over 5 years: stood at -$0.0 in 2021, then grew by 1.06% to -$0.0 in 2022, then tumbled by 4467.49% to -$0.12 in 2023, then increased by 8.33% to -$0.11 in 2024, then surged by 37.67% to -$0.07 in 2025.
  • Business Quant data shows EPS (Basic) for BDPT at -$0.07 in Q4 2025, -$0.03 in Q3 2025, and -$0.02 in Q2 2025.